List of Excipients in Branded Drug CLINDESSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis Israel Pharmaceuticals Ltd	CLINDESSE	clindamycin phosphate	45802-042	EDETATE DISODIUM
Padagis Israel Pharmaceuticals Ltd	CLINDESSE	clindamycin phosphate	45802-042	GLYCERYL ISOSTEARATE
Padagis Israel Pharmaceuticals Ltd	CLINDESSE	clindamycin phosphate	45802-042	LECITHIN, SOYBEAN
Padagis Israel Pharmaceuticals Ltd	CLINDESSE	clindamycin phosphate	45802-042	METHYLPARABEN
Padagis Israel Pharmaceuticals Ltd	CLINDESSE	clindamycin phosphate	45802-042	MICROCRYSTALLINE WAX

Clindesse Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Clindesse is a single-dose vaginal cream containing clindamycin phosphate 2%, equivalent to 100 mg clindamycin phosphate in a 5-gram applicator. Its commercial differentiation depends less on the active ingredient, which is an established generic antibiotic, and more on the vehicle, local tolerability, applicator design, latex compatibility, manufacturing consistency, and regulatory evidence supporting product performance.

The strongest development opportunities are a non-oily, latex-compatible cream; a bioadhesive or extended-residence formulation; a lower-mess unit-dose applicator; and a generic or authorized-generic product with equivalent clinical performance and improved user convenience.

What is the Clindesse formulation and which excipients does it contain?

Clindesse uses an oil-containing cream base with mineral oil, cetostearyl alcohol, glyceryl monostearate, polysorbate 60, propylene glycol, and purified water as inactive ingredients. The product delivers 5 grams of cream through a single-use vaginal applicator.[1]

Component	Likely formulation function	Commercial relevance
Mineral oil	Oil phase, emollient, consistency contributor	Creates an oil-based product but can compromise latex contraceptive devices
Cetostearyl alcohol	Structural fatty alcohol, thickener, stabilizer	Controls cream body and spreadability
Glyceryl monostearate	Emulsifier and consistency agent	Supports physical stability and texture
Polysorbate 60	Surfactant and emulsifier	Helps maintain dispersion of oil and aqueous phases
Propylene glycol	Solvent, humectant, penetration and wetting aid	Can affect local tolerability and osmolality
Purified water	Aqueous vehicle	Controls hydration, viscosity, and application feel
Clindamycin phosphate	Water-soluble antibiotic prodrug salt	Active pharmaceutical ingredient

The label identifies the formulation as oil-based and warns that latex condoms and diaphragms should not be relied upon during treatment and for five days after treatment.[1] That limitation is the clearest excipient-driven commercial weakness.

Why does the Clindesse excipient system matter commercially?

The vehicle determines how patients experience the product and how easily a competitor can differentiate an otherwise commoditized antibiotic.

Clindesse’s formulation has four commercial consequences:

1. The oil phase can create residue and leakage.
2. The oil base creates a contraceptive-device compatibility limitation.
3. The single-dose design reduces adherence burden compared with multi-day vaginal therapy.
4. The cream must balance clindamycin release with retention, spreadability, and local tolerability.

A generic manufacturer that copies the labeled inactive ingredients may obtain a relatively direct development path, but it also inherits the same latex-compatibility limitation. A differentiated product can compete on patient convenience even when the active ingredient, dose, and route are unchanged.

What formulation patents and intellectual-property rights protect Clindesse?

Clindamycin itself is an old small-molecule antibiotic, so composition-of-matter exclusivity does not provide a meaningful barrier for Clindesse. The relevant intellectual-property value lies in formulation claims, vaginal delivery systems, dosing regimens, applicator configuration, and manufacturing controls.

Formulation patent exposure

Potentially relevant claim categories include:

• Oil-in-water or water-in-oil vaginal cream systems
• Single-dose clindamycin vaginal formulations
• Defined ratios of mineral oil, fatty alcohols, emulsifiers, and glycols
• Controlled release or prolonged vaginal residence
• Prefilled applicators
• Methods for treating bacterial vaginosis with a single intravaginal dose
• Packaging that maintains dose uniformity and product stability

Public FDA labeling establishes the formulation and NDA history but does not, by itself, establish the current patent position. The FDA product record identifies Clindesse under NDA 021649.[2] Current Orange Book entries, patent-use codes, and any listed patents must be assessed against the specific product and dosage form before relying on a Paragraph IV strategy.

Because the product is a small-molecule vaginal cream, biosimilar litigation is not relevant. Any competitive challenge would proceed through an abbreviated new drug application, a 505(b)(2) application, or a full NDA, depending on the degree of formulation and clinical differentiation.

When does Clindesse lose exclusivity?

Clindesse’s active ingredient is long off patent. The commercial question is whether formulation, use, or regulatory exclusivity creates a remaining barrier.

Exclusivity category	Clindesse relevance
Active-ingredient patent	No meaningful remaining barrier for clindamycin
Formulation patent	Potentially relevant if claims remain enforceable
Method-of-use patent	Potentially relevant for bacterial-vaginosis treatment regimens
New chemical entity exclusivity	Expired
Three-year new clinical investigation exclusivity	Historical approval-related protection may have expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No material current barrier identified from the product’s established history
Biosimilar exclusivity	Not applicable

The practical entry barrier is therefore regulatory equivalence, manufacturing capability, product quality, and channel access rather than molecule-level exclusivity.

What FDA pathway is available for a Clindesse competitor?

ANDA pathway for a generic vaginal cream

An ANDA is the most direct route for a product that matches the reference product in active ingredient, strength, dosage form, route, and performance characteristics. A generic developer would need to establish pharmaceutical equivalence and bioequivalence under FDA requirements applicable to topical and vaginal products.

The principal development risks are:

• Demonstrating equivalent clindamycin availability at the site of action
• Matching viscosity, rheology, globule-size distribution, and pH
• Controlling assay and content uniformity across the 5-gram dose
• Demonstrating microbial quality and preservative performance, where applicable
• Establishing comparable drug release
• Managing device and container-closure differences
• Addressing the effect of the vehicle on local exposure

For a semisolid vaginal product, conventional plasma pharmacokinetics may not fully describe therapeutic equivalence. Product-specific in vitro release testing, comparative characterization, and, where required, clinical or pharmacodynamic evidence can affect development cost and timing.

505(b)(2) pathway for an improved formulation

A 505(b)(2) application is more appropriate for a product that retains clindamycin phosphate but materially changes the vehicle, dose delivery, residence time, or applicator.

Potential 505(b)(2) positioning includes:

• Latex-compatible delivery
• Reduced leakage
• Lower application volume
• Preservative-free formulation
• Mucoadhesive retention
• Extended release
• Improved tolerability
• Alternate applicator or dosing format

This route may support formulation patents and product-specific clinical claims. It also creates higher evidence requirements than a straightforward generic.

What excipient changes offer the strongest commercial opportunity?

1. Replace mineral oil with a latex-compatible vehicle

This is the clearest opportunity. A non-oily emulsion or hydrophilic cream could eliminate the five-day latex warning, assuming compatibility is demonstrated through appropriate testing and reflected in labeling.

Candidate vehicle strategies include:

• Medium-chain triglycerides
• Non-mineral-oil emollients
• Hydrophilic emulsions
• Polyethylene glycol-based systems
• Silicone-compatible systems
• Water-dispersible lipid systems

The replacement must preserve clindamycin stability, cream texture, vaginal tolerability, and drug release. A vehicle that improves contraceptive compatibility but increases burning, discharge, or leakage would have limited commercial value.

2. Introduce mucoadhesion and longer residence

A bioadhesive polymer can increase residence time and reduce post-dose leakage. Candidate materials may include carbomers, polycarbophil, cellulose derivatives, hyaluronic-acid-based systems, and selected thiolated polymers.

The principal design constraint is local tolerability. Excessive adhesion can increase discomfort and make the product difficult to remove. Polymer interactions can also slow clindamycin release or create nonuniform drug distribution.

3. Reduce viscosity and application mess

The current cream format delivers a relatively large 5-gram dose. A lower-volume formulation could improve patient acceptance if it maintains equivalent local exposure.

Commercial targets include:

• A 2- to 3-gram dose
• Faster spreading
• Lower residue
• Reduced leakage after administration
• A less visible or less disruptive post-dose experience

A lower-volume product would need strong evidence that reduced mass does not compromise drug distribution across the vagina.

4. Develop a thermoresponsive or in situ gelling system

A low-viscosity product that gels after administration could improve applicator filling and patient comfort while increasing retention after dosing. Useful mechanisms include temperature-triggered gelation or ion-sensitive polymers.

This approach has a higher technical and regulatory burden. The formulation must remain stable during storage, pass through the applicator consistently, and avoid rapid expulsion after administration.

5. Use a preservative-free single-dose system

Single-dose packaging can reduce the need for antimicrobial preservatives and may improve local tolerability. Clindesse already uses a unit-dose format, which supports this strategy.

A preservative-free product must still meet microbial limits and maintain container-closure integrity. The commercial advantage is strongest for patients who experience irritation from preservatives or repeated exposure to multi-dose products.

What manufacturing and excipient barriers affect Clindesse competition?

The manufacturing process is a potential barrier even when the ingredient list is simple. Semisolid vaginal products require tight control of:

• Emulsion formation
• Mixing temperature
• Cooling rate
• Shear history
• Particle or droplet size
• Viscosity
• Drug distribution
• Fill weight
• Applicator delivery force
• Microbial quality
• Stability under temperature excursions

Cetostearyl alcohol and glyceryl monostearate can produce significant changes in cream structure when temperature and cooling conditions vary. Polysorbate 60 concentration and mixing order can affect emulsion stability. Propylene glycol can influence water activity, viscosity, and patient sensation.

A company with established semisolid manufacturing and vaginal-dose packaging has an advantage over a manufacturer that primarily produces oral solids. Contract manufacturing capacity may be available, but technology transfer and scale-up can expose hidden variability in rheology and filling performance.

What generic entry risks exist for Clindesse?

Paragraph IV risk

A generic applicant could challenge any Orange Book-listed patent by filing a Paragraph IV certification. The commercial attractiveness depends on whether the asserted claims cover the specific inactive-ingredient composition, the single-dose regimen, or only narrow formulation parameters.

The main litigation theories would likely involve:

• Noninfringement based on a different excipient system
• Invalidity for obviousness
• Lack of written description or enablement
• Expired patent claims
• Failure of the listed patent to cover the proposed generic product

Formulation equivalence risk

A product may contain the same active ingredient and strength yet encounter regulatory difficulty if its vehicle materially changes drug release or local exposure. Vaginal creams are more sensitive to excipient changes than many immediate-release oral dosage forms.

Label and contraceptive compatibility risk

A copied oil-based formulation would retain the latex warning. A redesigned vehicle could gain a labeling advantage, but the claim must be supported by compatibility testing and approved labeling.

Safety risk

Clindamycin vaginal therapy is associated with local adverse reactions and carries the broader antibiotic risk of diarrhea and Clostridioides difficile-associated disease.[1] Excipients that increase irritation or alter absorption can affect the overall safety profile.

How does Clindesse compare with competing bacterial-vaginosis treatments?

Product category	Typical commercial distinction	Excipient opportunity
Clindesse single-dose cream	One administration, clindamycin phosphate	Improve vehicle, latex compatibility, and leakage
Multi-day clindamycin cream	Established generic competition	Compete on shorter treatment duration
Clindamycin vaginal ovules	Different dosage form and handling profile	Avoid cream residue and oil-base limitations
Metronidazole vaginal gel	Widely used alternative antibiotic	Compete on efficacy perception, tolerability, and dosing
Oral metronidazole or tinidazole	Systemic administration	Position local delivery for reduced systemic exposure
Secnidazole oral granules	Single-dose oral convenience	Vaginal products must justify local delivery and tolerability

Clindesse’s strongest positioning is single-dose local treatment. Its weakest positioning is the oil-based base and associated contraceptive-device warning.

Which companies could pursue Clindesse commercial opportunities?

The most likely competitors are:

• Generic manufacturers with semisolid vaginal production
• Companies with 505(b)(2) formulation platforms
• Women’s-health companies with gynecology sales forces
• Contract manufacturers that can produce unit-dose vaginal creams
• Specialty pharmaceutical companies seeking lifecycle extensions for established antibiotics

A generic entrant would compete primarily on price, supply reliability, and pharmacy coverage. A differentiated entrant would need a clear claim, such as latex compatibility, lower leakage, improved tolerability, or reduced dosing volume.

What is the revenue opportunity for an improved Clindesse product?

Revenue potential depends on market access rather than the value of clindamycin itself. A conventional generic would face rapid price erosion after multiple entrants. An improved formulation could preserve pricing if it obtains product-specific exclusivity, patents, or differentiated payer and prescriber positioning.

The most defensible commercial models are:

1. A low-cost authorized generic or branded generic.
2. A 505(b)(2) product with a latex-compatible formulation.
3. A single-dose, low-volume, bioadhesive formulation.
4. A co-branded women’s-health product supported by specialty distribution.
5. A licensing deal involving an excipient platform rather than clindamycin rights alone.

A licensee would value an excipient technology more highly if it can be reused across other vaginal products, including antifungals, hormones, probiotics, and nonhormonal contraceptives.

How strong is the Clindesse patent estate?

The estate is likely weak at the active-ingredient level and potentially stronger at the formulation level. Patent value depends on claim breadth, remaining term, Orange Book listing, prosecution history, and whether a competing product can avoid the claimed excipient ranges.

A narrow claim directed to mineral oil, cetostearyl alcohol, glyceryl monostearate, polysorbate 60, and propylene glycol may be avoidable through a redesigned vehicle. A broader claim covering the functional concept of a single-dose clindamycin vaginal cream would create a larger barrier but would face greater validity risk because of prior art involving vaginal clindamycin formulations.

Key Takeaways

• Clindesse contains 2% clindamycin phosphate in a 5-gram, single-dose vaginal cream.
• Its excipient system includes mineral oil, cetostearyl alcohol, glyceryl monostearate, polysorbate 60, propylene glycol, and purified water.
• Mineral oil is the principal commercial weakness because it creates a latex-condom and diaphragm compatibility warning lasting five days after treatment.
• The highest-value formulation opportunity is a latex-compatible, lower-residue vehicle.
• Mucoadhesive, low-volume, preservative-free, and thermoresponsive systems offer additional differentiation.
• A conventional generic would likely face price erosion and limited defensibility.
• A materially improved formulation could support a 505(b)(2) strategy, formulation patents, and premium positioning.
• Biosimilar risk does not apply because clindamycin is a small-molecule drug.
• Manufacturing control over emulsion structure, viscosity, fill weight, and applicator delivery is central to product quality.
• The active ingredient provides little current exclusivity; commercial value rests on formulation, delivery, regulatory strategy, and market access.

FAQs

Can a Clindesse generic use different excipients?

Yes. A generic may use different inactive ingredients if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, safety, and labeling.

Can a new Clindesse formulation remove the latex warning?

Potentially. Removing the warning would require a vehicle that does not weaken latex contraceptive devices and adequate compatibility evidence supporting the proposed labeling.

Is clindamycin phosphate suitable for a vaginal gel instead of a cream?

Yes. Clindamycin phosphate can be formulated in alternative vaginal dosage forms, but the change may require a 505(b)(2) application rather than a conventional ANDA if the product differs materially from the reference formulation.

Does Clindesse have biosimilar competition?

No. Biosimilar pathways apply to biologics. Clindesse contains clindamycin phosphate, a small-molecule active ingredient, so competition would come from generics or reformulated products.

What is the most defensible patent strategy for a new Clindesse product?

The strongest strategy would combine a broad but technically supportable vehicle claim with claims covering latex compatibility, reduced dosing volume, residence time, applicator delivery, and manufacturing controls.

References

1. U.S. Food and Drug Administration. (2018). Clindesse (clindamycin phosphate) vaginal cream, 2%: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Clindesse, NDA 021649. U.S. Department of Health and Human Services.